Article By:
Rod Raynovich
Sunday, January 3, 2016 10:00 PM EDT
We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015 and the Mid-Caps also beat despite a big loss by Clovis Oncology after the FDA required more data on its lung cancer drug.